PTAB invalidates Prevnar 13 patent

American pharmaceutical company Merck & Co. has secured a victory against its rival Pfizer in an inter partes review of a patent concerning Prevnar 13, the biggest-selling vaccine in the world.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

15 January 2026 The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.

Americas

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

15 January 2026 A court has blocked the patent owner's latest attempt to stop a generic rival as it weighs the right way to challenge a new product.

Americas

Why the US is poised for a patent litigation surge in 2026

12 January 2026 After “seismic” changes imposed by the USPTO last year, litigating patents will become significantly more difficult and costly to defend, and both plaintiffs and defendants must urgently retool their strategies, advise lawyers from BCLP.

More features

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Italian medtech startup beats larger US rival in UPC dispute

Senior USPTO solicitor steps into private practice

Goodwin targets transatlantic patent work with London hire

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

Carpmaels & Ransford builds Munich UPC team with elite hire

Why the US is poised for a patent litigation surge in 2026

PTAB invalidates Prevnar 13 patent

More on this story

Editor's picks

Editor's picks

More features